What is the catalog number for Linagliptin?

The catalog number for Linagliptin is HY-10284.

What sizes are available for Linagliptin?

Linagliptin is available in the following size(s): 10 mM - 1 mL, 100 mg, 500 mg, 1 g.

How many pack sizes does Linagliptin come in?

Linagliptin is available in 4 different pack sizes.

Is Linagliptin in stock?

Linagliptin is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Linagliptin?

Linagliptin is manufactured by QuantiMol.

What is the estimated delivery time for Linagliptin?

Estimated delivery time for Linagliptin is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Linagliptin?

The safety data sheet for Linagliptin is available here: http://file.medchemexpress.com/batch_PDF/HY-10284/Linagliptin-SDS-MedChemExpress.pdf.

Linagliptin

Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.

Product Specifications

CAS Number

668270-12-0

Product Name Alternative

BI 1356

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Autophagy; Dipeptidyl Peptidase; Ferroptosis

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Linagliptin.html

Purity

99.91

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1N(C2=C(C(N1CC3=NC(C)=C4C=CC=CC4=N3)=O)N(CC#CC)C(N5CCC[C@@H](N)C5)=N2)C

Molecular Formula

C25H28N8O2

Molecular Weight

472.54

Precautions

H315, H319, H335

References & Citations

[1]Eckhardt M, et al. 8- (3- (R) -aminopiperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 d|[2]Thomas L, et al. (R) -8- (3-amino-piperidin-1-yl) -7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action|[3]Schurmann C, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012 Jul;342 (1) :71-80.|[4]Huan Y, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017 Jun 28;7 (1) :4351.